How do you pay?

How to pay the least

Ask for the cash price

Nerlynx

We didn’t find one.

  1. Ask your pharmacy for Nerlynx’s cash price, and one or two other pharmacies too.
  2. Nerlynx’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameNerlynx
Authorized genericneratinib
Regular genericneratinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Nerlynx?
The original
–
–

Brand nameThe maker’s card

Nerlynx Co-Pay Card (Puma Patient Lynx)

Savings card from Puma Biotechnology

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $10 a prescription

Sign up on nerlynxhcp.com 

Or call 1-855-816-5421.

In the maker’s words

“Eligible commercially insured patients treated with NERLYNX may pay as little as $10 per prescription.”

From the maker’s offer on nerlynxhcp.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Nerlynx itself, from the same company, sold without the brand name, and usually for less. For now Nerlynx is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

NERLYNX is a kinase inhibitor indicated:

  • As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

Source: the FDA label for Nerlynx (Puma Biotechnology, Inc.), July 2, 2026. Full label on DailyMed 

Good to know